Lehigh Valley Health Network

LVHN Scholarly Works
Research Scholars Poster Presentation

Evaluation of Meningitis/Encephalitis (ME) Panel
in the Detection of Infectious Organisms in CSF of
Children
Alyssa Scott
Muhlenberg College

Tibisay Villalobos MD
Lehigh Valley Health Network, tibisay.villalobos@lvhn.org

Follow this and additional works at: http://scholarlyworks.lvhn.org/research-scholars-posters
Published In/Presented At
Scott, A., Villalobos-Fry, T., (2017, July, 31) Evaluation of Meningitis/Encephalitis (ME) Panel in the Detection of Infectious Organisms in
CSF of Children. Poster presented at LVHN Research Scholar Program Poster Session, Lehigh Valley Health Network, Allentown, PA.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an
authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Evaluation of Meningitis/Encephalitis (ME) Panel in the Detection of Infectious Organisms in CSF
of Children
Alyssa Scott and Tibisay Villalobos-Fry,MD,FAAP
Lehigh Valley Health Network, Allentown, Pennsylvania

BACKGROUND

RESULTS

• Central nervous system (CNS) infections are a common
reason for admission of infants and children to the hospital
and can lead to significant morbidity and mortality1
• Traditional diagnostic tests, such as bacterial culture, are
limited in their sensitivity and turnaround time2,3
• The Biofire FilmArray™ Meningitis/Encephalitis (ME) Panel is
a multiplex PCR panel that detects 14 bacteria, viruses, and
yeasts in cerebrospinal fluid (CSF)
• This ME panel was approved by the FDA in October 2015,
and was implemented at LVHN in February 2016
• This new molecular test may be of clinical value due to its
high sensitivity, rapid turnaround time, and ability to test for
multiple pathogens simultaneously1,2,4

Figure 1. Overview of ME panel results. All patients with
a positive ME panel were <2 years of age.
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Figure 2. Viruses identified by ME panel.
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METHODS
Retrospectively reviewed all FilmArray™ ME panels results
from February 1, 2016 to May 31, 2017 for patients <18
years of age
Collected the following data from EPIC™: demographic
information; admission and discharge dates; ME panel and
culture results; time of sample collection and results; and
antimicrobial duration

Analyzed collected data; used two-sample t-tests for analysis
of turnaround time, length of hospital stay, and
antimicrobial duration
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• The aim of this study is to evaluate the ME panel in children
admitted to the Lehigh Valley Children’s Hospital by:
• Comparing the ME Panel results to traditional bacterial
culture
• Analyzing clinical impact by measuring test turnaround
time, length of hospital stay, and antimicrobial duration

25 (19%) patients
w/positive ME panel

107 (81%) patients w/
negative ME panel

Enterovirus

Herpes virus 6

H. simplex 2

Table 1 Comparison of turnaround time for ME panel and CSF
culture
Test

No. of
results

Avg. turnaround
time (hrs)

Range (hrs)

ME panel

132

7.2*

(2.5-46.6)

CSF culture

131

28.4*

(13.1-84.1)

*significant difference between values (P < .05)

Table 2 Length of hospital stay for patients with positive and
negative ME panels
Avg. length of
Range
ME panel result
hospital stay (days) (days)
Bacteria detected
19
(7-26)
Virus detected *
3.1**
(1-10)
Negative
7.4**
(0-132)
*HSV excluded from calculations
**significant difference between values (P < .05)
Table 3 Antimicrobial duration in patients with positive and
negative ME panels
No. of
Avg. max duration of
ME panel result
patients antimicrobials (days)
21
Bacteria detected 3
Virus detected*
20
1.6**
Negative ME panel 107
3.8**
*HSV excluded from calculations
**significant difference between values (P < .05)
Table 4 Acyclovir duration in patients with possible HSV
infection
No. of
Avg. duration of acyclovir
ME panel result
patients
(days)
HSV detected
2
20.5
HSV not detected 36
0.89

CONCLUSION
• The faster turnaround time of ME panel compared to
traditional culture is valuable in making earlier
decisions about appropriate antimicrobial therapy
• Negative ME panel results for HSV allow for earlier
discontinuation of empiric acyclovir therapy (<24 hrs)
• Future studies are needed to further look into the
clinical impact of the ME panel, specifically the impact
on antibiotic use
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